Novo Nordisk Scraps Rare-Disease Plant and Unleashes High-Dose Data to Fortify GLP-1 Empire
Published on 05/16/2026 at 16:46 | Redaktion boerse-global.de
Novo Nordisk is playing hardball. The Danish drugmaker has pulled the plug on a planned factory for rare-disease treatments in Odense, converting the site into pure warehousing for its blockbuster GLP-1 drugs, while simultaneously publishing fresh clinical results that show its high-dose Wegovy melts fat without stripping muscle. The twin moves underscore a single-minded bet: obesity is the only game in town.
The strategic pivot arrives on the back of a robust first-quarter earnings report that comfortably beat expectations. Novo Nordisk generated nearly 97 billion Danish kroner in revenue during the first three months of 2026, with net profit landing at around 48.5 billion kroner. Adjusted earnings per share of $1.03 topped analyst forecasts, and management responded by raising the full-year guidance for both revenue and operating profit. The lift came despite a currency-adjusted 11% decline in US sales of the legacy diabetes portfolio, as surging Wegovy demand more than offset the pricing pressure stateside.
The decision to abandon the Odense rare-disease facility reflects a brutal prioritisation of resources. Novo Nordisk had originally earmarked the site for niche therapies, but production and logistics bottlenecks for the GLP-1 franchise have become so acute that the company is now channelling every available kroner into infrastructure for its weight-loss and diabetes bestsellers. The retooled site will serve purely as storage and distribution capacity for drugs like Wegovy and Ozempic, underscoring how urgently the group needs to ease supply constraints.
On the clinical front, Novo Nordisk fired a direct salvo at rival Eli Lilly. Data from the STEP-UP trial, presented at the European Congress on Obesity in Istanbul, showed that patients on the 7.2mg weekly dose of Wegovy lost an average of 21% of their body weight over 72 weeks — roughly 23 kilograms for a typical participant. Crucially, MRI scans of a subgroup revealed that 84% of the lost weight was fat, while lean muscle mass declined by only 10%. A standardised chair-stand test confirmed that muscle function remained intact, addressing a key concern that has dogged the entire GLP-1 class.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The high-dose regimen also produced a cohort of rapid responders: about 27% of patients shed at least 15% of their body weight within the first 24 weeks, and this group went on to achieve a weight loss of almost 28% by week 72. With that performance, Novo Nordisk closes the efficacy gap with Lilly’s Zepbound, which has long boasted average weight reductions north of 20%. The high-dose version of Wegovy is already reaching patients in the US, having been added to formularies by major pharmacy-benefit managers.
But competition is closing in from multiple directions. The US Food and Drug Administration recently approved Foundayo, a new oral GLP-1 pill developed by Eli Lilly, giving patients a convenience advantage that could erode Novo Nordisk's share in the oral segment. Meanwhile, the generics threat is materialising: Dr. Reddy’s Laboratories launched a copycat version of semaglutide in Canada, marking the first such entry in a G7 economy after key patents expired in India in March. Patent cliffs loom in China and Canada, with copycat manufacturers already lining up.
Institutional investors have responded to the shifting landscape with sharply divergent bets. Franklin Resources increased its Novo Nordisk stake by more than 4,000%, while Capital International Investors added 52.4% to its position. Atria Investments, by contrast, trimmed its holdings by 9.3%. On the analyst side, Wall Street Zen upgraded the shares to "Buy" over the weekend, citing the strong quarterly print and promising data from the oral obesity pipeline.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
All of this leaves the stock at an inflection point. Novo Nordisk shares closed Friday at €38.51, a gain of nearly 12% over the past month but still down 13.81% year-to-date. The relative strength index stands at 33.9, a technically oversold reading that historically has preceded rebounds. The yawning gap from the stock’s annual high of around €70 tells the story of a company that has taken a beating from pricing pressures and patent expiries — but one now marshalling its resources for the next phase of the fight.
Ad
Novo Nordisk Stock: New Analysis - 16 May
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
